Key Opinion Leaders React to NIAGARA at #ESMO24
Total Impressions 59,776
Top Tweets
Sentiment Analysis
| Doctor Name |
Sentiment |
Comment |
|
Neeraj Agarwal, MD, FASCO |
POSITIVE
|
Fantastic discussion of the Niagara trial results by master @PGrivasMDPhD in the @myESMO #ESMO24 presidential session👉Comparison with other adjuvant trials👇perioperative durvalumab with cisplatin chemo is new standard of care due to OS benefit @urotoday @OncoAlert https://t.co/0Vu6oHkZst https://t.co/jvZNdaoF4w |
|
Petros Grivas |
POSITIVE
|
Fantastic atmosphere in Barcelona Presidential symposium with practice changing data including NIAGARA trial #bladdercancer @myESMO #ESMO24 #ESMOAmbassadors @OncoAlert @Uromigos @tompowles1 @DrChoueiri @MyriamChalabi @lab_kok @curijoey @KKronig @AndresC27622123 @peters_solange https://t.co/0KfdqnuyiJ https://t.co/8Hsc3ufYqS |
|
Neeraj Agarwal, MD, FASCO |
POSITIVE
|
Breaking news (practice changing) from @myESMO #ESMO24 👉@tompowles1 presents the 1st results of the ph3 Niagara trial of cisplatin + gemcitabine +|- durvalumab in MIBC #bladdercancer 👉Significant improvement in DFS (HR 0.68) & OS (HR 0.75) with durvalumab @OncoAlert @urotoday https://t.co/CsipAvOLe8 |
|
Toni Choueiri, MD |
POSITIVE
|
NIAGARA. Chemo +Durva is a NEW SOC in HIGH RISK PERIOP Muscle-Invasive Bladder Cancer #ESMO24. @tompowles1 does it again! Concomitant @NEJM paper! https://t.co/6H7JzrZnsm |
|
Javier Puente |
POSITIVE
|
#ESMO24 @tompowles1 has presented another practice changing bladder trial!! periop GC+Durva, meets EFS+OS NIAGARA trial Congrats!!!!! https://t.co/EXn2fXAEDf |
|
Tian Zhang, MD, MHS |
POSITIVE
|
Masterful discussion from @PGrivasMDPhD -- placing #NIAGARA in context of our #bladdercancer practice -- neoadjuvant and adjuvant OS benefits. Patients are living longer from earlier use of IO agents. Proposes future trial designs. @myESMO #ESMO24 #ESMOAmbassadors @OncoAlert https://t.co/UDtmsD84Ni |
|
Shilpa Gupta |
POSITIVE
|
#ESMO24 The indomitable & humble @tompowles1 does it again w/ the large practice changing NIAGARA! neoadjuavnt GC durvalumab & adjuvant durva improves EFS & OS compared to GC in MIBC! @montypal @neerajaiims @PGrivasMDPhD @DrRosenbergMSK @apolo_andrea @UroDocAsh @DrChoueiri https://t.co/m4K1q0U9L0 |
|
Sabine D. Brookman-May |
NEUTRAL
|
The right questions addressed by @PGrivasMDPhD after NIAGARA trial presentation: ❓should we proceed with adjuvant treatment in ypT0? ❓Is there a role of ctDNA for adjuvant treatment decisions ❓can pts be cured with systemic therapy #BladderSparing approach? @oncodaily #MIBC https://t.co/h9wAhkPSbt |
|
Sergio Vázquez |
NEUTRAL
|
NIAGARA: Probably a new SoC, but we don’t know if it’s better than adjuvant immunotherapy in operable bladder cancer. The pCR is not statistically significant. Fantastic discussion by @PGrivasMDPhD #ESMO24 #bladdecancer https://t.co/SatsnffhvP |
|
Dr Amol Akhade |
NEUTRAL
|
Good discussion @PGrivasMDPhD 👌 👍 many unanswered questions. Important one is Post progression therapy for control arm ? Not there in published paper also ? This is important Data as was asked during discussion. We will need that to see that @VPrasadMDMPH @Timothee_MD @myESMO… https://t.co/DxWMYriziv https://t.co/YmemcNSaMr |
|
Jason Brown |
NEUTRAL
|
The awaited Niagara results are here @tompowles1. Perioperative Durvalumab shows clear PFS and OS benefit in MIBC. 💉pCR rate 33% ‼️PFS HR 0.68 👍🏻OS HR 0.75 ❓ Is adjuvant IO needed for all patients? https://t.co/ZIf5IH68EU |
|
Vinay Prasad MD MPH |
NEGATIVE
|
@SuyogCancer @PGrivasMDPhD @Timothee_MD @myESMO The authors have not even looked at post recurrence data. I think this is a new low @NEJM should have made them report this as condition to publish. Sad day for doctors who want to read science and be able to analyze it properly |
|
Vinay Prasad MD MPH |
NEGATIVE
|
@SuyogCancer @tompowles1 The authors have not even explored post-recurrence data. Pretty bad |
|
Timothée Olivier, MD |
NEGATIVE
|
Where are post-recurrence data? Not available. NIAGARA enrolled in LMIC countries with limited access to best post-recurrence care, which likely led to positive OS. Despite high expectations, NIAGARA did not have a standing ovation, and this is a good sign for oncology! https://t.co/IRvgi78f9H https://t.co/ISWhYi4MWw https://t.co/8fXUNKohQ2 |